个性化医学发展中的组织间交易趋势。

Trends in interorganizational transactions in personalized medicine development.

机构信息

Graduate School of Technology Management, Ritsumeikan University, 2-150, Iwakuracho, Ibaraki-shi, Osaka 567-8570, Japan.

Department of Innovation Science, School of Environment and Society, Tokyo Institute of Technology, Meguro-ku, Tokyo, Japan.

出版信息

Drug Discov Today. 2019 Feb;24(2):364-370. doi: 10.1016/j.drudis.2018.09.022. Epub 2018 Oct 16.

DOI:10.1016/j.drudis.2018.09.022

PMID:30339822

Abstract

Personalized medicine is an innovative concept that allows patients with a validated companion diagnosis (CoDx) to receive treatment using the most suitable drug. Currently, a major movement in the pharmaceutical industry involves the integrated use of multiple resources from external sources. To ascertain preferable interorganizational collaborations and their suitable exits, we compared the related transactions in personalized and nonpersonalized cancer drugs. We found that there were significantly more of some alliance deals in personalized medicine, and that market licenses, one of the exits, were well correlated with other alliances only in personalized medicine. Furthermore, four types of collaboration mode were identified, and more active collaborations with external partners were found to lead to more successful outcomes in personalized medicine development.

摘要

个体化医学是一种创新理念，允许经验证的伴随诊断（CoDx）患者使用最合适的药物进行治疗。目前，制药行业的一个主要动向是整合利用来自外部资源的多种资源。为了确定更好的组织间合作及其合适的退出策略，我们比较了个体化和非个体化癌症药物的相关交易。我们发现，个体化医学中某些联盟交易的数量明显更多，并且市场许可（退出策略之一）仅在个体化医学中与其他联盟高度相关。此外，还确定了四种协作模式，并发现与外部合作伙伴更积极的合作会导致个体化医学开发的更成功结果。